| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rectal Neoplasms | 86 | 2022 | 1240 | 5.220 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 42 | 2019 | 481 | 3.380 |
Why?
|
| Colorectal Neoplasms | 73 | 2024 | 3707 | 2.790 |
Why?
|
| Anus Neoplasms | 17 | 2022 | 414 | 1.700 |
Why?
|
| Colectomy | 15 | 2019 | 292 | 1.630 |
Why?
|
| Adenocarcinoma | 61 | 2022 | 7914 | 1.610 |
Why?
|
| Adenomatous Polyposis Coli | 21 | 2016 | 226 | 1.540 |
Why?
|
| Neoplasm Recurrence, Local | 53 | 2024 | 10400 | 1.270 |
Why?
|
| Digestive System Surgical Procedures | 9 | 2017 | 275 | 1.120 |
Why?
|
| Colonic Neoplasms | 18 | 2016 | 1435 | 0.920 |
Why?
|
| DNA Mismatch Repair | 8 | 2019 | 283 | 0.850 |
Why?
|
| Neoplastic Syndromes, Hereditary | 7 | 2019 | 232 | 0.760 |
Why?
|
| Neoadjuvant Therapy | 26 | 2022 | 5231 | 0.690 |
Why?
|
| Microsatellite Repeats | 11 | 2004 | 627 | 0.660 |
Why?
|
| Pelvic Exenteration | 4 | 2007 | 112 | 0.660 |
Why?
|
| Neoplasm Staging | 53 | 2022 | 14012 | 0.630 |
Why?
|
| Middle Aged | 156 | 2024 | 90352 | 0.610 |
Why?
|
| Chemoradiotherapy | 13 | 2022 | 2027 | 0.600 |
Why?
|
| Male | 179 | 2024 | 128315 | 0.580 |
Why?
|
| Aged | 136 | 2024 | 73333 | 0.560 |
Why?
|
| Pelvic Neoplasms | 5 | 2018 | 199 | 0.560 |
Why?
|
| Humans | 247 | 2024 | 270740 | 0.550 |
Why?
|
| Carcinoma | 13 | 2017 | 2610 | 0.540 |
Why?
|
| Female | 182 | 2024 | 148940 | 0.540 |
Why?
|
| Neoplasms, Multiple Primary | 7 | 2016 | 557 | 0.520 |
Why?
|
| Morbidity | 4 | 2014 | 400 | 0.510 |
Why?
|
| Insurance, Health | 3 | 2007 | 261 | 0.510 |
Why?
|
| Combined Modality Therapy | 41 | 2017 | 9039 | 0.510 |
Why?
|
| Genetic Testing | 16 | 2022 | 1696 | 0.510 |
Why?
|
| Adult | 135 | 2021 | 82040 | 0.500 |
Why?
|
| Survival Rate | 42 | 2024 | 12541 | 0.500 |
Why?
|
| Carcinoma, Squamous Cell | 18 | 2022 | 5593 | 0.500 |
Why?
|
| Surgeons | 1 | 2021 | 491 | 0.490 |
Why?
|
| Germ-Line Mutation | 17 | 2019 | 1101 | 0.490 |
Why?
|
| Hepatectomy | 5 | 2012 | 1015 | 0.490 |
Why?
|
| Retrospective Studies | 83 | 2024 | 39890 | 0.470 |
Why?
|
| Postoperative Complications | 18 | 2017 | 5681 | 0.470 |
Why?
|
| Lymphatic Metastasis | 24 | 2024 | 4963 | 0.470 |
Why?
|
| Prognosis | 52 | 2024 | 22505 | 0.460 |
Why?
|
| Carcinoma in Situ | 2 | 2017 | 489 | 0.450 |
Why?
|
| Microsatellite Instability | 5 | 2021 | 408 | 0.450 |
Why?
|
| Aged, 80 and over | 66 | 2017 | 30998 | 0.410 |
Why?
|
| Fluorouracil | 18 | 2022 | 1990 | 0.400 |
Why?
|
| Rectum | 9 | 2022 | 480 | 0.400 |
Why?
|
| Follow-Up Studies | 34 | 2024 | 15218 | 0.380 |
Why?
|
| DNA, Neoplasm | 9 | 2016 | 1958 | 0.360 |
Why?
|
| Genetic Predisposition to Disease | 16 | 2019 | 5776 | 0.360 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 21 | 2022 | 16689 | 0.350 |
Why?
|
| Liver Neoplasms | 15 | 2017 | 4821 | 0.320 |
Why?
|
| Mucins | 1 | 2010 | 289 | 0.310 |
Why?
|
| Salvage Therapy | 6 | 2017 | 2123 | 0.310 |
Why?
|
| Health Status Indicators | 1 | 2009 | 234 | 0.310 |
Why?
|
| Lymph Node Excision | 5 | 2024 | 2062 | 0.300 |
Why?
|
| Lymph Nodes | 8 | 2024 | 3077 | 0.290 |
Why?
|
| MutS Homolog 2 Protein | 7 | 2017 | 179 | 0.290 |
Why?
|
| Brachytherapy | 1 | 2014 | 1005 | 0.280 |
Why?
|
| Ileostomy | 3 | 2018 | 47 | 0.280 |
Why?
|
| Genetic Markers | 4 | 2019 | 1075 | 0.280 |
Why?
|
| Life Style | 2 | 2021 | 618 | 0.280 |
Why?
|
| Chemoradiotherapy, Adjuvant | 6 | 2017 | 562 | 0.280 |
Why?
|
| SEER Program | 8 | 2015 | 1047 | 0.280 |
Why?
|
| Chemotherapy, Adjuvant | 15 | 2017 | 4000 | 0.270 |
Why?
|
| Re-Irradiation | 2 | 2018 | 166 | 0.260 |
Why?
|
| Genomic Instability | 3 | 2006 | 521 | 0.260 |
Why?
|
| Colorectal Surgery | 3 | 2016 | 35 | 0.260 |
Why?
|
| Radiotherapy, Adjuvant | 11 | 2015 | 2271 | 0.250 |
Why?
|
| Time Factors | 18 | 2017 | 13006 | 0.250 |
Why?
|
| DNA-Binding Proteins | 10 | 2017 | 5002 | 0.250 |
Why?
|
| Survivors | 4 | 2017 | 1021 | 0.250 |
Why?
|
| Intestinal Polyps | 5 | 2002 | 79 | 0.250 |
Why?
|
| Treatment Outcome | 44 | 2022 | 33737 | 0.250 |
Why?
|
| Peutz-Jeghers Syndrome | 2 | 2006 | 59 | 0.250 |
Why?
|
| Neoplasms, Second Primary | 5 | 2003 | 1388 | 0.250 |
Why?
|
| Duodenal Neoplasms | 4 | 2002 | 138 | 0.250 |
Why?
|
| Age Factors | 13 | 2019 | 5457 | 0.240 |
Why?
|
| DNA Sequence, Unstable | 1 | 2004 | 7 | 0.230 |
Why?
|
| Hamartoma Syndrome, Multiple | 2 | 2001 | 38 | 0.230 |
Why?
|
| Perineum | 6 | 2008 | 115 | 0.220 |
Why?
|
| MutL Protein Homolog 1 | 6 | 2019 | 206 | 0.220 |
Why?
|
| Anal Canal | 7 | 2017 | 236 | 0.220 |
Why?
|
| Interleukin-10 | 1 | 2006 | 483 | 0.210 |
Why?
|
| Disease-Free Survival | 17 | 2021 | 10265 | 0.210 |
Why?
|
| Young Adult | 22 | 2021 | 22251 | 0.210 |
Why?
|
| Capecitabine | 7 | 2019 | 390 | 0.210 |
Why?
|
| Survival Analysis | 24 | 2018 | 9292 | 0.200 |
Why?
|
| Neoplasm Invasiveness | 8 | 2018 | 4048 | 0.200 |
Why?
|
| Fibromatosis, Aggressive | 3 | 2005 | 110 | 0.200 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2001 | 2453 | 0.200 |
Why?
|
| Incidence | 13 | 2018 | 5824 | 0.200 |
Why?
|
| Interferon-gamma | 1 | 2006 | 1179 | 0.190 |
Why?
|
| Deoxycytidine | 6 | 2013 | 1389 | 0.190 |
Why?
|
| Medical Oncology | 5 | 2014 | 1465 | 0.190 |
Why?
|
| Quality Indicators, Health Care | 2 | 2015 | 354 | 0.190 |
Why?
|
| Adolescent | 29 | 2021 | 32767 | 0.190 |
Why?
|
| Celecoxib | 5 | 2015 | 198 | 0.190 |
Why?
|
| Quality of Life | 6 | 2017 | 4761 | 0.190 |
Why?
|
| Pathology, Clinical | 1 | 2002 | 129 | 0.190 |
Why?
|
| Wounds and Injuries | 1 | 2005 | 437 | 0.180 |
Why?
|
| Mutation | 15 | 2016 | 15912 | 0.180 |
Why?
|
| Health Services Accessibility | 1 | 2007 | 831 | 0.180 |
Why?
|
| Sigmoidoscopy | 4 | 2016 | 49 | 0.180 |
Why?
|
| Quality Control | 1 | 2002 | 461 | 0.180 |
Why?
|
| Risk Assessment | 12 | 2018 | 6764 | 0.180 |
Why?
|
| United States | 20 | 2019 | 15861 | 0.180 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2001 | 1126 | 0.180 |
Why?
|
| Spouses | 1 | 2021 | 140 | 0.180 |
Why?
|
| Pedigree | 9 | 2017 | 2042 | 0.180 |
Why?
|
| Quality Assurance, Health Care | 2 | 2015 | 596 | 0.170 |
Why?
|
| Parotid Neoplasms | 2 | 1991 | 150 | 0.170 |
Why?
|
| Age of Onset | 8 | 2016 | 853 | 0.170 |
Why?
|
| Base Pair Mismatch | 6 | 2006 | 82 | 0.170 |
Why?
|
| Chromosome Aberrations | 4 | 2001 | 2035 | 0.170 |
Why?
|
| Radiotherapy | 7 | 2018 | 1857 | 0.170 |
Why?
|
| Insurance Coverage | 2 | 1999 | 275 | 0.170 |
Why?
|
| Risk Factors | 21 | 2016 | 17888 | 0.160 |
Why?
|
| Eating | 1 | 2001 | 448 | 0.160 |
Why?
|
| Radiotherapy Dosage | 11 | 2018 | 4019 | 0.160 |
Why?
|
| Fertility Preservation | 1 | 2021 | 151 | 0.160 |
Why?
|
| DNA, Satellite | 1 | 1999 | 44 | 0.160 |
Why?
|
| Enteral Nutrition | 1 | 2001 | 347 | 0.160 |
Why?
|
| Pelvis | 4 | 2019 | 381 | 0.160 |
Why?
|
| Adenomatous Polyps | 3 | 2015 | 45 | 0.160 |
Why?
|
| Registries | 5 | 2009 | 2211 | 0.160 |
Why?
|
| Anastomosis, Surgical | 4 | 2013 | 370 | 0.160 |
Why?
|
| Polymerase Chain Reaction | 13 | 2017 | 3476 | 0.160 |
Why?
|
| Adenocarcinoma, Mucinous | 3 | 2014 | 442 | 0.160 |
Why?
|
| Dissection | 3 | 2003 | 132 | 0.160 |
Why?
|
| Ileal Neoplasms | 2 | 1995 | 49 | 0.160 |
Why?
|
| Hepatic Veins | 1 | 1998 | 59 | 0.160 |
Why?
|
| Insurance, Life | 1 | 1998 | 3 | 0.160 |
Why?
|
| Abdominal Neoplasms | 2 | 2005 | 251 | 0.150 |
Why?
|
| Mass Screening | 3 | 2019 | 1552 | 0.150 |
Why?
|
| Insurance, Disability | 1 | 1998 | 3 | 0.150 |
Why?
|
| Bile Ducts | 1 | 1998 | 115 | 0.150 |
Why?
|
| Heterozygote | 3 | 2007 | 1056 | 0.150 |
Why?
|
| DNA Repair | 9 | 2010 | 1909 | 0.150 |
Why?
|
| Hydronephrosis | 2 | 2001 | 51 | 0.150 |
Why?
|
| Surgical Wound Dehiscence | 2 | 2009 | 127 | 0.150 |
Why?
|
| Carcinoma, Signet Ring Cell | 3 | 2014 | 180 | 0.150 |
Why?
|
| Practice Guidelines as Topic | 5 | 2014 | 2400 | 0.140 |
Why?
|
| Portal Vein | 2 | 2001 | 363 | 0.140 |
Why?
|
| Intestine, Small | 3 | 2000 | 522 | 0.140 |
Why?
|
| Health Behavior | 1 | 2021 | 601 | 0.140 |
Why?
|
| Biomarkers, Tumor | 8 | 2019 | 10708 | 0.140 |
Why?
|
| Radioimmunodetection | 2 | 1995 | 21 | 0.140 |
Why?
|
| Medical Errors | 2 | 2015 | 210 | 0.140 |
Why?
|
| Endoscopy, Gastrointestinal | 2 | 1998 | 375 | 0.140 |
Why?
|
| Neoplasm, Residual | 4 | 2013 | 1754 | 0.140 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 1 | 2016 | 49 | 0.140 |
Why?
|
| Preoperative Care | 7 | 2013 | 1567 | 0.140 |
Why?
|
| Cryotherapy | 1 | 1996 | 67 | 0.140 |
Why?
|
| Technetium | 2 | 1995 | 79 | 0.140 |
Why?
|
| Energy Intake | 1 | 2019 | 521 | 0.140 |
Why?
|
| Prospective Studies | 17 | 2022 | 13414 | 0.140 |
Why?
|
| Cryosurgery | 1 | 1998 | 196 | 0.140 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 1996 | 107 | 0.140 |
Why?
|
| Carcinoid Tumor | 1 | 1998 | 282 | 0.130 |
Why?
|
| Multivariate Analysis | 7 | 2012 | 4328 | 0.130 |
Why?
|
| Gastroenterologists | 1 | 2016 | 21 | 0.130 |
Why?
|
| Jejunal Neoplasms | 1 | 1995 | 32 | 0.130 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2018 | 180 | 0.130 |
Why?
|
| Sex Factors | 6 | 2013 | 2184 | 0.130 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 2 | 2015 | 198 | 0.130 |
Why?
|
| Proportional Hazards Models | 8 | 2016 | 5101 | 0.130 |
Why?
|
| Prevalence | 4 | 2019 | 3404 | 0.120 |
Why?
|
| Eflornithine | 1 | 2015 | 60 | 0.120 |
Why?
|
| Radiation Injuries | 4 | 2009 | 1471 | 0.120 |
Why?
|
| Tumor Burden | 4 | 2015 | 2033 | 0.120 |
Why?
|
| Fibromatosis, Abdominal | 1 | 1994 | 9 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2017 | 6256 | 0.120 |
Why?
|
| Defecation | 1 | 2014 | 57 | 0.120 |
Why?
|
| Colonic Pseudo-Obstruction | 1 | 1994 | 4 | 0.120 |
Why?
|
| Cancer Survivors | 1 | 2021 | 742 | 0.120 |
Why?
|
| Rectal Diseases | 2 | 2009 | 57 | 0.120 |
Why?
|
| Colonoscopes | 1 | 1994 | 24 | 0.120 |
Why?
|
| Cisplatin | 4 | 2022 | 2497 | 0.110 |
Why?
|
| Occult Blood | 1 | 1994 | 63 | 0.110 |
Why?
|
| Diet | 1 | 2021 | 1477 | 0.110 |
Why?
|
| Exosomes | 1 | 2016 | 255 | 0.110 |
Why?
|
| Precision Medicine | 2 | 2019 | 1207 | 0.110 |
Why?
|
| Neoplasm Metastasis | 7 | 2016 | 5315 | 0.110 |
Why?
|
| Diagnosis, Differential | 8 | 2010 | 4831 | 0.110 |
Why?
|
| Polymorphism, Genetic | 5 | 2006 | 1557 | 0.110 |
Why?
|
| Intestinal Neoplasms | 2 | 1994 | 205 | 0.110 |
Why?
|
| Colonic Pouches | 1 | 2013 | 8 | 0.110 |
Why?
|
| Proctocolectomy, Restorative | 1 | 2013 | 17 | 0.110 |
Why?
|
| Patient Selection | 4 | 2015 | 2025 | 0.110 |
Why?
|
| Superior Mesenteric Artery Syndrome | 1 | 2013 | 8 | 0.110 |
Why?
|
| Socioeconomic Factors | 3 | 2013 | 1267 | 0.110 |
Why?
|
| Carcinoembryonic Antigen | 7 | 2007 | 231 | 0.110 |
Why?
|
| Computer Communication Networks | 1 | 2013 | 43 | 0.110 |
Why?
|
| Feasibility Studies | 5 | 2021 | 2353 | 0.100 |
Why?
|
| Life Expectancy | 1 | 2013 | 129 | 0.100 |
Why?
|
| Colon | 4 | 2001 | 659 | 0.100 |
Why?
|
| Endometrial Neoplasms | 2 | 2019 | 1385 | 0.100 |
Why?
|
| Antibodies, Monoclonal | 5 | 2009 | 4481 | 0.100 |
Why?
|
| Stomach Neoplasms | 4 | 2017 | 2331 | 0.100 |
Why?
|
| Bevacizumab | 3 | 2013 | 967 | 0.100 |
Why?
|
| Computer Simulation | 1 | 2017 | 1570 | 0.100 |
Why?
|
| Bandages | 1 | 1992 | 75 | 0.100 |
Why?
|
| Health Status Disparities | 1 | 2015 | 318 | 0.100 |
Why?
|
| Antibodies, Neoplasm | 1 | 1992 | 273 | 0.100 |
Why?
|
| Colonoscopy | 5 | 2016 | 522 | 0.100 |
Why?
|
| Cohort Studies | 10 | 2017 | 9470 | 0.100 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2019 | 1336 | 0.100 |
Why?
|
| Photochemotherapy | 3 | 2000 | 116 | 0.100 |
Why?
|
| Loss of Heterozygosity | 4 | 2001 | 623 | 0.090 |
Why?
|
| Surgical Flaps | 3 | 2008 | 894 | 0.090 |
Why?
|
| Antimetabolites, Antineoplastic | 5 | 2006 | 1347 | 0.090 |
Why?
|
| Self-Help Groups | 1 | 2011 | 36 | 0.090 |
Why?
|
| Bacterial Infections | 3 | 2009 | 510 | 0.090 |
Why?
|
| Nomograms | 1 | 2013 | 312 | 0.090 |
Why?
|
| Antineoplastic Agents | 9 | 2019 | 14617 | 0.090 |
Why?
|
| New York | 4 | 1996 | 103 | 0.090 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2017 | 880 | 0.090 |
Why?
|
| Phenols | 1 | 1991 | 105 | 0.090 |
Why?
|
| Rosaniline Dyes | 4 | 2007 | 109 | 0.090 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2002 | 177 | 0.090 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2022 | 2178 | 0.090 |
Why?
|
| Adenolymphoma | 1 | 1990 | 25 | 0.090 |
Why?
|
| Leucovorin | 5 | 2008 | 345 | 0.090 |
Why?
|
| Neoplasm Grading | 4 | 2016 | 1823 | 0.090 |
Why?
|
| Digestive System Neoplasms | 1 | 2000 | 79 | 0.090 |
Why?
|
| Odds Ratio | 3 | 2014 | 2311 | 0.090 |
Why?
|
| Disclosure | 1 | 2011 | 180 | 0.090 |
Why?
|
| Precancerous Conditions | 2 | 2000 | 1059 | 0.080 |
Why?
|
| Texas | 5 | 2018 | 6449 | 0.080 |
Why?
|
| Pain, Intractable | 1 | 1991 | 180 | 0.080 |
Why?
|
| Predictive Value of Tests | 4 | 2015 | 4960 | 0.080 |
Why?
|
| Anus Diseases | 1 | 2009 | 28 | 0.080 |
Why?
|
| Surgical Mesh | 3 | 2000 | 212 | 0.080 |
Why?
|
| Endosonography | 3 | 2012 | 551 | 0.080 |
Why?
|
| Nerve Block | 1 | 1991 | 184 | 0.080 |
Why?
|
| Genetic Variation | 1 | 2017 | 2166 | 0.080 |
Why?
|
| Metformin | 1 | 2013 | 393 | 0.080 |
Why?
|
| Neoplasms | 7 | 2021 | 15927 | 0.080 |
Why?
|
| Medical Records | 2 | 2008 | 442 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2019 | 7895 | 0.080 |
Why?
|
| Hypoglycemic Agents | 1 | 2013 | 599 | 0.080 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2004 | 2617 | 0.080 |
Why?
|
| Sacrum | 1 | 2009 | 138 | 0.080 |
Why?
|
| Robotics | 1 | 2012 | 365 | 0.070 |
Why?
|
| Adenoma | 1 | 2013 | 740 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2002 | 540 | 0.070 |
Why?
|
| Rehabilitation Nursing | 1 | 2007 | 11 | 0.070 |
Why?
|
| Spinal Fractures | 1 | 2009 | 138 | 0.070 |
Why?
|
| Surgical Stomas | 1 | 2007 | 24 | 0.070 |
Why?
|
| Bowen's Disease | 2 | 2000 | 10 | 0.070 |
Why?
|
| Sulfonamides | 4 | 2013 | 1933 | 0.070 |
Why?
|
| Pain | 3 | 2010 | 1694 | 0.070 |
Why?
|
| Benchmarking | 2 | 2021 | 275 | 0.070 |
Why?
|
| Access to Information | 1 | 2007 | 52 | 0.070 |
Why?
|
| Palliative Care | 5 | 2014 | 2178 | 0.070 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 1340 | 0.070 |
Why?
|
| Social Adjustment | 1 | 2007 | 114 | 0.070 |
Why?
|
| Research | 1 | 2009 | 427 | 0.070 |
Why?
|
| Education, Medical, Graduate | 1 | 1993 | 705 | 0.070 |
Why?
|
| Linear Models | 1 | 2009 | 1093 | 0.070 |
Why?
|
| Paget Disease, Extramammary | 2 | 2000 | 54 | 0.070 |
Why?
|
| Immunoenzyme Techniques | 3 | 2007 | 1189 | 0.070 |
Why?
|
| Genome, Human | 3 | 2006 | 1888 | 0.070 |
Why?
|
| Ovarian Neoplasms | 2 | 1999 | 4795 | 0.070 |
Why?
|
| Confidence Intervals | 3 | 2015 | 749 | 0.060 |
Why?
|
| Academic Medical Centers | 1 | 2009 | 681 | 0.060 |
Why?
|
| Sensitivity and Specificity | 8 | 2007 | 5162 | 0.060 |
Why?
|
| Genes, p53 | 3 | 2000 | 1140 | 0.060 |
Why?
|
| Remission Induction | 3 | 2010 | 3656 | 0.060 |
Why?
|
| Safety | 1 | 2007 | 460 | 0.060 |
Why?
|
| Severity of Illness Index | 1 | 2016 | 4372 | 0.060 |
Why?
|
| Salivary Gland Neoplasms | 1 | 1989 | 497 | 0.060 |
Why?
|
| Internet | 1 | 2009 | 690 | 0.060 |
Why?
|
| Minisatellite Repeats | 1 | 2005 | 66 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2005 | 1903 | 0.060 |
Why?
|
| Pain Management | 1 | 2010 | 712 | 0.060 |
Why?
|
| Obesity | 1 | 2017 | 2904 | 0.060 |
Why?
|
| Pilot Projects | 3 | 2021 | 2828 | 0.060 |
Why?
|
| Chemokines | 1 | 2006 | 290 | 0.060 |
Why?
|
| Interleukin-15 | 1 | 2006 | 190 | 0.060 |
Why?
|
| Colostomy | 3 | 2013 | 80 | 0.060 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2006 | 368 | 0.060 |
Why?
|
| Surveys and Questionnaires | 5 | 2017 | 5923 | 0.060 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 1 | 2004 | 113 | 0.060 |
Why?
|
| Population Surveillance | 3 | 2016 | 647 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2018 | 3557 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2012 | 6224 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2013 | 3409 | 0.060 |
Why?
|
| Activities of Daily Living | 1 | 2007 | 539 | 0.060 |
Why?
|
| Surgical Wound Infection | 1 | 2008 | 495 | 0.060 |
Why?
|
| Polyps | 2 | 1996 | 81 | 0.060 |
Why?
|
| Drug Therapy | 1 | 2004 | 205 | 0.060 |
Why?
|
| Organ Sparing Treatments | 2 | 2017 | 283 | 0.060 |
Why?
|
| DNA Methylation | 2 | 2004 | 2765 | 0.060 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2004 | 72 | 0.060 |
Why?
|
| Age Distribution | 2 | 2015 | 727 | 0.060 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2006 | 314 | 0.060 |
Why?
|
| Colitis, Ulcerative | 2 | 1996 | 258 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2016 | 2887 | 0.050 |
Why?
|
| Prostatic Neoplasms | 3 | 2007 | 5866 | 0.050 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 1998 | 197 | 0.050 |
Why?
|
| Societies, Medical | 3 | 2006 | 1320 | 0.050 |
Why?
|
| Peritoneal Neoplasms | 3 | 2005 | 859 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 6 | 2010 | 1470 | 0.050 |
Why?
|
| Genes, APC | 2 | 2005 | 71 | 0.050 |
Why?
|
| Carcinoma, Papillary | 1 | 1997 | 566 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 714 | 0.050 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2007 | 1458 | 0.050 |
Why?
|
| Exercise | 2 | 2021 | 1184 | 0.050 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2006 | 631 | 0.050 |
Why?
|
| Medical History Taking | 1 | 2003 | 175 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 1412 | 0.050 |
Why?
|
| Brain Neoplasms | 2 | 2016 | 4958 | 0.050 |
Why?
|
| Video Recording | 2 | 2016 | 281 | 0.050 |
Why?
|
| Netherlands | 1 | 2002 | 90 | 0.050 |
Why?
|
| Consensus | 2 | 2018 | 1106 | 0.050 |
Why?
|
| Neoplasm Proteins | 4 | 2004 | 3345 | 0.050 |
Why?
|
| Logistic Models | 4 | 2013 | 3444 | 0.050 |
Why?
|
| Alleles | 4 | 2006 | 2600 | 0.050 |
Why?
|
| Wound Healing | 4 | 2008 | 749 | 0.050 |
Why?
|
| Comorbidity | 1 | 2008 | 2394 | 0.050 |
Why?
|
| Reoperation | 3 | 2013 | 1392 | 0.050 |
Why?
|
| Patient Care Team | 1 | 2007 | 823 | 0.050 |
Why?
|
| Abscess | 2 | 2008 | 192 | 0.050 |
Why?
|
| Statistics, Nonparametric | 3 | 2010 | 984 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2012 | 2650 | 0.050 |
Why?
|
| Viruses | 2 | 1993 | 157 | 0.050 |
Why?
|
| Risk | 3 | 2014 | 1939 | 0.050 |
Why?
|
| Urinary Bladder Fistula | 1 | 2000 | 14 | 0.050 |
Why?
|
| ROC Curve | 2 | 2016 | 1248 | 0.050 |
Why?
|
| Rectal Fistula | 1 | 2000 | 7 | 0.050 |
Why?
|
| Mitomycin | 1 | 2022 | 213 | 0.050 |
Why?
|
| Gene Silencing | 1 | 2004 | 827 | 0.050 |
Why?
|
| Recurrence | 4 | 2016 | 4878 | 0.050 |
Why?
|
| Genes, ras | 1 | 2004 | 679 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2002 | 558 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2006 | 1584 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 2 | 2006 | 1109 | 0.040 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 3 | 2006 | 192 | 0.040 |
Why?
|
| Isoenzymes | 2 | 2000 | 648 | 0.040 |
Why?
|
| Margins of Excision | 1 | 2022 | 315 | 0.040 |
Why?
|
| Treatment Failure | 3 | 2008 | 1430 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2022 | 417 | 0.040 |
Why?
|
| Pseudomyxoma Peritonei | 1 | 1999 | 41 | 0.040 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2000 | 231 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 3597 | 0.040 |
Why?
|
| Documentation | 1 | 2021 | 213 | 0.040 |
Why?
|
| Drug Administration Schedule | 3 | 2013 | 3530 | 0.040 |
Why?
|
| Sequence Analysis | 1 | 2019 | 80 | 0.040 |
Why?
|
| Enteritis | 1 | 1999 | 67 | 0.040 |
Why?
|
| Clinical Chemistry Tests | 1 | 1999 | 11 | 0.040 |
Why?
|
| Intraoperative Period | 2 | 1998 | 251 | 0.040 |
Why?
|
| Surgical Stapling | 1 | 1998 | 35 | 0.040 |
Why?
|
| Periodicity | 1 | 1999 | 71 | 0.040 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2000 | 136 | 0.040 |
Why?
|
| Fertility | 1 | 2021 | 336 | 0.040 |
Why?
|
| Vitamins | 1 | 2019 | 149 | 0.040 |
Why?
|
| Radiopharmaceuticals | 1 | 2004 | 1341 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2000 | 338 | 0.040 |
Why?
|
| Phenotype | 4 | 2004 | 6509 | 0.040 |
Why?
|
| Carboplatin | 2 | 2014 | 880 | 0.040 |
Why?
|
| Genotype | 5 | 2006 | 4252 | 0.040 |
Why?
|
| Health Status | 1 | 2021 | 631 | 0.040 |
Why?
|
| Omentum | 2 | 1999 | 108 | 0.040 |
Why?
|
| Point Mutation | 1 | 2001 | 788 | 0.040 |
Why?
|
| Videoconferencing | 1 | 2018 | 52 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1999 | 298 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2006 | 3339 | 0.040 |
Why?
|
| Gene Expression | 1 | 2006 | 3640 | 0.040 |
Why?
|
| Quality Improvement | 2 | 2015 | 914 | 0.040 |
Why?
|
| Leukemia | 2 | 1996 | 1719 | 0.040 |
Why?
|
| Diagnostic Tests, Routine | 1 | 1999 | 168 | 0.040 |
Why?
|
| Ovariectomy | 1 | 1998 | 371 | 0.040 |
Why?
|
| Appendicitis | 1 | 1999 | 177 | 0.040 |
Why?
|
| Pyrazoles | 4 | 2013 | 1546 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 1999 | 287 | 0.040 |
Why?
|
| Carrier Proteins | 5 | 2005 | 2098 | 0.040 |
Why?
|
| China | 1 | 2019 | 636 | 0.040 |
Why?
|
| Incidental Findings | 1 | 2019 | 282 | 0.040 |
Why?
|
| Education | 1 | 1997 | 125 | 0.040 |
Why?
|
| Frameshift Mutation | 1 | 1998 | 234 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2012 | 7783 | 0.040 |
Why?
|
| Disease Progression | 5 | 2013 | 6867 | 0.040 |
Why?
|
| Smoking | 1 | 2006 | 2555 | 0.030 |
Why?
|
| Fissure in Ano | 1 | 1996 | 8 | 0.030 |
Why?
|
| Informed Consent | 1 | 2000 | 415 | 0.030 |
Why?
|
| Chi-Square Distribution | 2 | 2012 | 1312 | 0.030 |
Why?
|
| Appendiceal Neoplasms | 1 | 1999 | 251 | 0.030 |
Why?
|
| Folic Acid | 1 | 2019 | 369 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2005 | 2115 | 0.030 |
Why?
|
| Immunoglobulin Fab Fragments | 2 | 1995 | 93 | 0.030 |
Why?
|
| Child | 8 | 2017 | 30559 | 0.030 |
Why?
|
| Premedication | 1 | 1996 | 133 | 0.030 |
Why?
|
| HCT116 Cells | 1 | 2017 | 354 | 0.030 |
Why?
|
| Vagina | 1 | 1998 | 331 | 0.030 |
Why?
|
| Family | 2 | 1997 | 783 | 0.030 |
Why?
|
| Sulfasalazine | 1 | 2016 | 12 | 0.030 |
Why?
|
| Laparotomy | 2 | 1999 | 235 | 0.030 |
Why?
|
| Liquid Biopsy | 1 | 2016 | 164 | 0.030 |
Why?
|
| Tegafur | 1 | 1996 | 51 | 0.030 |
Why?
|
| Observer Variation | 2 | 2013 | 709 | 0.030 |
Why?
|
| Uracil | 1 | 1996 | 66 | 0.030 |
Why?
|
| Ileum | 1 | 1996 | 167 | 0.030 |
Why?
|
| Contraindications | 1 | 1996 | 154 | 0.030 |
Why?
|
| Thyroid Neoplasms | 1 | 1997 | 1894 | 0.030 |
Why?
|
| Trans-Activators | 2 | 1999 | 1624 | 0.030 |
Why?
|
| Human papillomavirus 18 | 1 | 2015 | 42 | 0.030 |
Why?
|
| Splenectomy | 1 | 1996 | 168 | 0.030 |
Why?
|
| DNA Glycosylases | 1 | 2015 | 88 | 0.030 |
Why?
|
| Keratins | 2 | 2007 | 340 | 0.030 |
Why?
|
| Antidotes | 1 | 1995 | 27 | 0.030 |
Why?
|
| Polyurethanes | 1 | 2014 | 37 | 0.030 |
Why?
|
| Postoperative Care | 1 | 1999 | 728 | 0.030 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1996 | 425 | 0.030 |
Why?
|
| Metastasectomy | 1 | 2017 | 209 | 0.030 |
Why?
|
| Body Weight | 1 | 2019 | 1307 | 0.030 |
Why?
|
| Hemagglutination Tests | 1 | 1994 | 28 | 0.030 |
Why?
|
| Syndrome | 1 | 1997 | 1407 | 0.030 |
Why?
|
| Guaiac | 1 | 1994 | 6 | 0.030 |
Why?
|
| Swine | 1 | 1998 | 1607 | 0.030 |
Why?
|
| Nuclear Proteins | 5 | 2005 | 3438 | 0.030 |
Why?
|
| Endonucleases | 1 | 1995 | 184 | 0.030 |
Why?
|
| Li-Fraumeni Syndrome | 1 | 2015 | 166 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2013 | 1269 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2013 | 84 | 0.030 |
Why?
|
| Endoscopic Mucosal Resection | 1 | 2016 | 117 | 0.030 |
Why?
|
| Organs at Risk | 1 | 2017 | 559 | 0.030 |
Why?
|
| Human papillomavirus 16 | 1 | 2015 | 255 | 0.030 |
Why?
|
| Animals | 8 | 2017 | 61956 | 0.030 |
Why?
|
| Mutation Rate | 1 | 2014 | 220 | 0.030 |
Why?
|
| Drugs, Investigational | 1 | 1995 | 130 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2015 | 497 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2015 | 361 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2015 | 1049 | 0.030 |
Why?
|
| Exons | 1 | 2017 | 1383 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2005 | 4644 | 0.030 |
Why?
|
| Matched-Pair Analysis | 2 | 2006 | 100 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2019 | 997 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 2017 | 813 | 0.030 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 1998 | 625 | 0.030 |
Why?
|
| Mathematical Concepts | 1 | 2013 | 13 | 0.030 |
Why?
|
| Renal Nutcracker Syndrome | 1 | 2013 | 7 | 0.030 |
Why?
|
| Feeding Behavior | 1 | 2019 | 817 | 0.030 |
Why?
|
| Crohn Disease | 1 | 1996 | 328 | 0.030 |
Why?
|
| Octreotide | 1 | 1993 | 131 | 0.030 |
Why?
|
| Proctoscopy | 1 | 2012 | 18 | 0.030 |
Why?
|
| Nasal Cavity | 1 | 1993 | 154 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2013 | 398 | 0.030 |
Why?
|
| Fluid Therapy | 1 | 1993 | 192 | 0.030 |
Why?
|
| Analysis of Variance | 1 | 1996 | 2315 | 0.030 |
Why?
|
| Fiber Optic Technology | 1 | 1993 | 146 | 0.030 |
Why?
|
| Immunoglobulin A | 1 | 1993 | 271 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 1568 | 0.020 |
Why?
|
| Ultrasonography | 1 | 1998 | 1933 | 0.020 |
Why?
|
| DNA Mutational Analysis | 3 | 2005 | 2357 | 0.020 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 600 | 0.020 |
Why?
|
| Phenol | 1 | 1991 | 18 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2015 | 1571 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 917 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 1992 | 316 | 0.020 |
Why?
|
| Spinal Nerve Roots | 1 | 1991 | 69 | 0.020 |
Why?
|
| Health Personnel | 1 | 2017 | 652 | 0.020 |
Why?
|
| Prostatectomy | 2 | 2007 | 1003 | 0.020 |
Why?
|
| Colonic Polyps | 1 | 1994 | 228 | 0.020 |
Why?
|
| Tumor Virus Infections | 1 | 1992 | 248 | 0.020 |
Why?
|
| Telemedicine | 1 | 2018 | 552 | 0.020 |
Why?
|
| Injections, Spinal | 1 | 1991 | 273 | 0.020 |
Why?
|
| Europe | 1 | 2012 | 658 | 0.020 |
Why?
|
| Reproducibility of Results | 3 | 2013 | 6177 | 0.020 |
Why?
|
| Stomach | 1 | 1993 | 402 | 0.020 |
Why?
|
| Puerto Rico | 1 | 2010 | 67 | 0.020 |
Why?
|
| Disease Models, Animal | 3 | 2001 | 7381 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2013 | 1322 | 0.020 |
Why?
|
| Radiotherapy, Conformal | 1 | 2015 | 898 | 0.020 |
Why?
|
| Skin Neoplasms | 2 | 2000 | 4895 | 0.020 |
Why?
|
| Patient Readmission | 1 | 2014 | 572 | 0.020 |
Why?
|
| Diarrhea | 1 | 1993 | 716 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 2359 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2017 | 2232 | 0.020 |
Why?
|
| Aftercare | 1 | 2011 | 252 | 0.020 |
Why?
|
| Proteins | 1 | 1997 | 2043 | 0.020 |
Why?
|
| Research Design | 2 | 2007 | 1569 | 0.020 |
Why?
|
| Cell Line | 1 | 2016 | 5338 | 0.020 |
Why?
|
| Intestines | 1 | 1993 | 736 | 0.020 |
Why?
|
| Quinazolines | 1 | 2013 | 956 | 0.020 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2012 | 509 | 0.020 |
Why?
|
| Fibroblasts | 1 | 1995 | 1654 | 0.020 |
Why?
|
| Medicare | 1 | 2014 | 926 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 3917 | 0.020 |
Why?
|
| Aloe | 1 | 1988 | 7 | 0.020 |
Why?
|
| Retreatment | 1 | 2009 | 448 | 0.020 |
Why?
|
| Plants, Medicinal | 1 | 1988 | 49 | 0.020 |
Why?
|
| Laser Therapy | 1 | 1993 | 466 | 0.020 |
Why?
|
| Genomics | 1 | 2019 | 2835 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 1992 | 907 | 0.020 |
Why?
|
| Economics, Medical | 1 | 2007 | 14 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1994 | 1067 | 0.020 |
Why?
|
| Biopsy | 3 | 2002 | 3484 | 0.020 |
Why?
|
| Drainage | 2 | 2003 | 462 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2006 | 12103 | 0.020 |
Why?
|
| Seminal Vesicles | 1 | 2007 | 149 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2012 | 1034 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2014 | 2101 | 0.020 |
Why?
|
| Lymphoma | 1 | 1996 | 1519 | 0.020 |
Why?
|
| Burns | 1 | 1988 | 130 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 2250 | 0.020 |
Why?
|
| Rectus Abdominis | 1 | 2008 | 92 | 0.020 |
Why?
|
| Health Promotion | 1 | 2011 | 510 | 0.020 |
Why?
|
| Gamma Rays | 1 | 2008 | 237 | 0.020 |
Why?
|
| DNA Damage | 1 | 1995 | 1989 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2009 | 704 | 0.020 |
Why?
|
| Genes, bcl-1 | 1 | 2006 | 25 | 0.020 |
Why?
|
| Family Health | 1 | 2007 | 349 | 0.020 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2006 | 130 | 0.020 |
Why?
|
| Survival | 1 | 2006 | 183 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 1992 | 1301 | 0.020 |
Why?
|
| Genes, bcl-2 | 1 | 2006 | 172 | 0.020 |
Why?
|
| Double-Blind Method | 2 | 2002 | 2580 | 0.020 |
Why?
|
| Anti-Infective Agents | 1 | 2009 | 466 | 0.020 |
Why?
|
| Mesentery | 1 | 2005 | 74 | 0.020 |
Why?
|
| Reference Values | 2 | 2000 | 1133 | 0.020 |
Why?
|
| Cytosine | 1 | 2006 | 155 | 0.020 |
Why?
|
| Communication | 1 | 2011 | 839 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2009 | 632 | 0.020 |
Why?
|
| Urinary Bladder | 1 | 2007 | 593 | 0.020 |
Why?
|
| Clinical Competence | 1 | 1993 | 1325 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2017 | 9042 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 2005 | 453 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 4492 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 7655 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2005 | 603 | 0.010 |
Why?
|
| Hospitalization | 1 | 2013 | 2167 | 0.010 |
Why?
|
| Ki-67 Antigen | 1 | 2006 | 675 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2006 | 425 | 0.010 |
Why?
|
| Gene Amplification | 2 | 1998 | 766 | 0.010 |
Why?
|
| Apoptosis | 1 | 1998 | 7757 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2005 | 303 | 0.010 |
Why?
|
| Abdomen | 2 | 1997 | 347 | 0.010 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2005 | 437 | 0.010 |
Why?
|
| Clinical Protocols | 1 | 2005 | 477 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 2004 | 655 | 0.010 |
Why?
|
| Abdominal Wall | 1 | 2005 | 193 | 0.010 |
Why?
|
| Plasmids | 1 | 2005 | 936 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2006 | 401 | 0.010 |
Why?
|
| Adenine | 1 | 2006 | 674 | 0.010 |
Why?
|
| Laparoscopy | 1 | 2012 | 1302 | 0.010 |
Why?
|
| Pyridines | 1 | 2009 | 1313 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2006 | 1608 | 0.010 |
Why?
|
| Base Sequence | 2 | 1999 | 5437 | 0.010 |
Why?
|
| Algorithms | 1 | 2013 | 3891 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2007 | 1184 | 0.010 |
Why?
|
| Infusions, Intravenous | 2 | 1995 | 1437 | 0.010 |
Why?
|
| Molecular Sequence Data | 2 | 1999 | 6685 | 0.010 |
Why?
|
| Blood Gas Analysis | 1 | 2001 | 107 | 0.010 |
Why?
|
| Codon, Terminator | 1 | 2000 | 43 | 0.010 |
Why?
|
| Laboratories | 1 | 2001 | 132 | 0.010 |
Why?
|
| Smad5 Protein | 1 | 1999 | 28 | 0.010 |
Why?
|
| Smad1 Protein | 1 | 1999 | 35 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2000 | 5056 | 0.010 |
Why?
|
| Intestinal Mucosa | 2 | 1998 | 1105 | 0.010 |
Why?
|
| Smad2 Protein | 1 | 1999 | 89 | 0.010 |
Why?
|
| International Cooperation | 1 | 2001 | 325 | 0.010 |
Why?
|
| Receptors, Progesterone | 1 | 2005 | 1604 | 0.010 |
Why?
|
| Mice | 2 | 2017 | 35600 | 0.010 |
Why?
|
| Smad Proteins | 1 | 1999 | 82 | 0.010 |
Why?
|
| Radiation-Protective Agents | 1 | 1999 | 129 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2005 | 2313 | 0.010 |
Why?
|
| Cost Control | 1 | 1999 | 45 | 0.010 |
Why?
|
| Dogs | 1 | 2001 | 1160 | 0.010 |
Why?
|
| Smad3 Protein | 1 | 1999 | 123 | 0.010 |
Why?
|
| Case Management | 1 | 1999 | 37 | 0.010 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2000 | 264 | 0.010 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2000 | 751 | 0.010 |
Why?
|
| Electrolytes | 1 | 1999 | 63 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2006 | 3216 | 0.010 |
Why?
|
| Lod Score | 1 | 1998 | 173 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 1999 | 233 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 1999 | 185 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1999 | 471 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 2000 | 822 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2006 | 2573 | 0.010 |
Why?
|
| Blood Chemical Analysis | 1 | 1999 | 113 | 0.010 |
Why?
|
| Electrophoresis | 1 | 1998 | 75 | 0.010 |
Why?
|
| Liver | 2 | 2001 | 3086 | 0.010 |
Why?
|
| Methods | 1 | 1998 | 223 | 0.010 |
Why?
|
| Hyperplasia | 1 | 1999 | 564 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2000 | 495 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2005 | 2170 | 0.010 |
Why?
|
| Polyglycolic Acid | 1 | 1997 | 38 | 0.010 |
Why?
|
| Water-Electrolyte Imbalance | 1 | 1999 | 98 | 0.010 |
Why?
|
| Smad4 Protein | 1 | 1998 | 201 | 0.010 |
Why?
|
| Hospital Costs | 1 | 1999 | 244 | 0.010 |
Why?
|
| Erythrocyte Transfusion | 1 | 1999 | 206 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 1999 | 300 | 0.010 |
Why?
|
| Lung Neoplasms | 2 | 2017 | 12033 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2002 | 1234 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 1998 | 354 | 0.010 |
Why?
|
| Tetrahydrofolates | 1 | 1996 | 20 | 0.010 |
Why?
|
| Chromosome Breakage | 1 | 1996 | 225 | 0.010 |
Why?
|
| Haplotypes | 1 | 1998 | 910 | 0.010 |
Why?
|
| Forecasting | 1 | 1998 | 702 | 0.010 |
Why?
|
| Hyperbilirubinemia | 1 | 1996 | 78 | 0.010 |
Why?
|
| Hematoporphyrin Derivative | 1 | 1995 | 2 | 0.010 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 1996 | 152 | 0.010 |
Why?
|
| Ampulla of Vater | 1 | 1996 | 160 | 0.010 |
Why?
|
| DNA Primers | 1 | 1998 | 1496 | 0.010 |
Why?
|
| Gene Deletion | 1 | 2000 | 1474 | 0.010 |
Why?
|
| Rats, Inbred F344 | 1 | 1995 | 239 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 1995 | 257 | 0.010 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2000 | 1012 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 1995 | 176 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 1995 | 413 | 0.010 |
Why?
|
| Digestive System | 1 | 1995 | 121 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 1999 | 518 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2000 | 1192 | 0.010 |
Why?
|
| Groin | 1 | 1994 | 78 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 1999 | 964 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1999 | 1824 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1995 | 721 | 0.010 |
Why?
|
| Floxuridine | 1 | 1994 | 41 | 0.010 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 1995 | 334 | 0.010 |
Why?
|
| Phosphoproteins | 1 | 1999 | 1138 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 1995 | 356 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1998 | 1655 | 0.010 |
Why?
|
| Blood Glucose | 1 | 1999 | 1269 | 0.010 |
Why?
|
| Cell Hypoxia | 1 | 1995 | 353 | 0.010 |
Why?
|
| Intraoperative Care | 1 | 1995 | 274 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2006 | 3658 | 0.010 |
Why?
|
| Dihematoporphyrin Ether | 1 | 1992 | 16 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1995 | 572 | 0.010 |
Why?
|
| Cytopathogenic Effect, Viral | 1 | 1992 | 38 | 0.010 |
Why?
|
| Insulin | 1 | 1999 | 1483 | 0.010 |
Why?
|
| Anemia | 1 | 1999 | 728 | 0.010 |
Why?
|
| Fibrosis | 1 | 1995 | 733 | 0.010 |
Why?
|
| Chromosome Deletion | 1 | 1996 | 1049 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 1996 | 719 | 0.010 |
Why?
|
| Pancreatic Neoplasms | 1 | 1989 | 5257 | 0.010 |
Why?
|
| Blood Loss, Surgical | 1 | 1993 | 295 | 0.010 |
Why?
|
| Length of Stay | 1 | 1999 | 2007 | 0.010 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 1995 | 550 | 0.010 |
Why?
|
| Endoscopy, Digestive System | 1 | 1992 | 210 | 0.010 |
Why?
|
| Genome | 1 | 1995 | 690 | 0.010 |
Why?
|
| Acute Kidney Injury | 1 | 1999 | 761 | 0.010 |
Why?
|
| Translocation, Genetic | 1 | 1996 | 1286 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 1996 | 2345 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2000 | 17061 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 1999 | 1024 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 1993 | 581 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2000 | 2928 | 0.010 |
Why?
|
| DNA | 1 | 1998 | 3050 | 0.010 |
Why?
|
| Multiple Sclerosis | 1 | 1993 | 375 | 0.010 |
Why?
|
| Pancreatic Diseases | 1 | 1989 | 113 | 0.000 |
Why?
|
| Silver Sulfadiazine | 1 | 1988 | 14 | 0.000 |
Why?
|
| Occlusive Dressings | 1 | 1988 | 14 | 0.000 |
Why?
|
| Ointments | 1 | 1988 | 23 | 0.000 |
Why?
|
| Salicylates | 1 | 1988 | 73 | 0.000 |
Why?
|
| Guinea Pigs | 1 | 1988 | 252 | 0.000 |
Why?
|
| Cysts | 1 | 1989 | 205 | 0.000 |
Why?
|
| Gels | 1 | 1988 | 106 | 0.000 |
Why?
|
| Wound Infection | 1 | 1988 | 66 | 0.000 |
Why?
|
| Administration, Topical | 1 | 1988 | 258 | 0.000 |
Why?
|
| Rats | 1 | 1995 | 6441 | 0.000 |
Why?
|
| Infant | 1 | 2000 | 13999 | 0.000 |
Why?
|
| Anti-Bacterial Agents | 1 | 1996 | 3187 | 0.000 |
Why?
|